C. Harris Spiridonidis

1.2k total citations
23 papers, 1.0k citations indexed

About

C. Harris Spiridonidis is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, C. Harris Spiridonidis has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in C. Harris Spiridonidis's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). C. Harris Spiridonidis is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Treatment and Pharmacology (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). C. Harris Spiridonidis collaborates with scholars based in United States, Germany and Italy. C. Harris Spiridonidis's co-authors include Agnieszka Woźniak, KS Albain, R. B. Livingston, Geoffrey R. Weiss, Karen Kelly, John J. Crowley, S P Balcerzak, Lawrence Baker, David R. Gandara and Leslie R. Laufman and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

C. Harris Spiridonidis

23 papers receiving 964 citations

Peers

Countries citing papers authored by C. Harris Spiridonidis

Since Specialization

Citations

This map shows the geographic impact of C. Harris Spiridonidis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Harris Spiridonidis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Harris Spiridonidis more than expected).

Fields of papers citing papers by C. Harris Spiridonidis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Harris Spiridonidis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Harris Spiridonidis. The network helps show where C. Harris Spiridonidis may publish in the future.

Co-authorship network of co-authors of C. Harris Spiridonidis

This figure shows the co-authorship network connecting the top 25 collaborators of C. Harris Spiridonidis. A scholar is included among the top collaborators of C. Harris Spiridonidis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Harris Spiridonidis. C. Harris Spiridonidis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Gemcitabine and Cisplatin in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group Study 9718 2007 ·Journal of Thoracic Oncology ·Paul J. Hesketh, Kari Chansky, Valerie K. Israel, (unknown), Tarek Mekhail, C. Harris Spiridonidis, Glenn Mills, Karen Kelly, John J. Crowley, David R. Gandara	3
2	Phase I Study of Doxil® and Vinorelbine in Patients with Advanced Malignancies 2004 ·Cancer Investigation ·Leslie R. Laufman, C. Harris Spiridonidis, (unknown), (unknown), Karen A. Rossi, (unknown)	5
3	An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59–8862) in patients with taxane-resistant non-small cell lung cancer 2004 ·Journal of Clinical Oncology ·Jayne Gurtler, Joachim von Pawel, C. Harris Spiridonidis, Francesco Grossi, J.L. González-Larriba, M. Moscovici, (unknown), D. Voliotis, Maya Gottfried	6
4	Dose-Intense Chemotherapy Every 2 Weeks With Dose-Intense Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone May Improve Survival in Intermediate- and High-Grade Lymphoma: A Phase II Study of the Southwest Oncology Group (SWOG 9349) 2003 ·Journal of Clinical Oncology ·Douglas W. Blayney, Michael LeBlanc, Thomas M. Grogan, Ellen R. Gaynor, Robert Chapman, C. Harris Spiridonidis, Sarah A. Taylor, Scott I. Bearman, Thomas P. Miller, Richard I. Fisher	63
5	Combination of Fludarabine and Mitoxantrone in Untreated Stages III and IV Low-Grade Lymphoma: S9501 2003 ·Journal of Clinical Oncology ·William S. Velasquez, Danika L. Lew, Thomas M. Grogan, C. Harris Spiridonidis, Stanley P. Balcerzak, Shaker R. Dakhil, Thomas P. Miller, Keith S. Lanier, Robert Chapman, Richard I. Fisher	43
6	Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: A phase II trial 2001 ·Annals of Oncology ·C. Harris Spiridonidis, Leslie R. Laufman, (unknown), Timothy M. Moore, (unknown), J. B. Jones, (unknown), Tejal Patel, Ralph W. Roach, (unknown), Jeffrey Zangmeister, (unknown), (unknown)	40
7	Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: A phase II trial 2001 ·Annals of Oncology ·Leslie R. Laufman, C. Harris Spiridonidis, (unknown), Ralph W. Roach, Jeffrey Zangmeister, (unknown), Timothy M. Moore, Michal Segal, J. B. Jones, Tejal Patel, Lorence A. Gutterman, (unknown), (unknown), J. Philip Kuebler	46
8	Docetaxel and Gemcitabine Combinations in Chemotherapy-Pretreated Non–Small-Cell Lung Cancer 2000 ·Clinical Lung Cancer ·C. Harris Spiridonidis, Leslie R. Laufman	4
9	Daily times four vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A phase II trial of a novel schedule 1999 ·Annals of Oncology ·C. Harris Spiridonidis, Leslie R. Laufman, J. B. Jones, (unknown)	4
10	Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. 1998 ·Journal of Clinical Oncology ·Agnieszka Woźniak, John J. Crowley, S P Balcerzak, Geoffrey R. Weiss, C. Harris Spiridonidis, Lawrence Baker, KS Albain, Karen Kelly, (unknown), David R. Gandara, R. B. Livingston	462
11	Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. 1998 ·Journal of Clinical Oncology ·C. Harris Spiridonidis, Leslie R. Laufman, J. B. Jones, (unknown), (unknown), Steven J. Nicol	58
12	CODE (Cisplatin, Vincristine, Doxorubicin, Etoposide) Plus Granulocyte Colony-Stimulating Factor in Advanced Non-Small-Cell Lung Cancer 1998 ·American Journal of Clinical Oncology ·Alan Sandler, Charles D. Blanke, Francesco Monaco, Mark Carey, Rafat Ansari, Beth Fisher, C. Harris Spiridonidis, Lawrence H. Einhorn, Craig R. Nichols	2
13	A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma 1996 ·Investigational New Drugs ·Kathy D. Miller, Patrick J. Loehrer, René Gonin, George Weber, Rafat Ansari, (unknown), J. McClean, C. Harris Spiridonidis, Joanne Mortimer	8
14	Photodynamic therapy for esophageal malignancy: A prospective twelve-year study 1996 ·The Annals of Thoracic Surgery ·James S. McCaughan, E. Christopher Ellison, (unknown), William J. Hicks, (unknown), Leslie R. Laufman, Eugene F. May, Thomas A. Nims, C. Harris Spiridonidis, Thomas E. Williams	84
15	Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. 1996 ·Journal of Clinical Oncology ·Jeffrey Crawford, Mark Allen O’Rourke, Joan H. Schiller, C. Harris Spiridonidis, Saul Yanovich, Howard Ozer, Adrian Langleben, Laura F. Hutchins, Alan J. Koletsky, Gerald H. Clamon, (unknown), Rebekah R. White, John Hohneker, (unknown)	100
16	A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma 1996 ·Cancer ·C. Harris Spiridonidis, Leslie R. Laufman, (unknown), (unknown), (unknown), Donn C. Young	24
17	Phase II Evaluation of Low-Dose Continuous 5-Fluorouracil and Weekly Cisplatin in Advanced Adenocarcinoma of the Stomach 1995 ·American Journal of Clinical Oncology ·Stephen K. Williamson, Catherine M. Tangen, Anne‐Marie Maddox, C. Harris Spiridonidis, John S. Macdonald	6
18	Decline of posttreatment tumor marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor 1995 ·Cancer ·C. Harris Spiridonidis, Leslie R. Laufman, (unknown), (unknown), (unknown), William J. Hicks, (unknown), (unknown), Donn C. Young, Bernard L. Zidar	9
19	Phase II Trial of Merbarone in Pancreatic Carcinoma 1993 ·American Journal of Clinical Oncology ·Eric H. Kraut, Thomas R. Fleming, John S. Macdonald, C. Harris Spiridonidis, James E. Bradof, Laurence H. Baker	8
20	Paclitaxel (Taxol): A novel antineoplastic agent 1993 ·Drugs of today ·C. Harris Spiridonidis	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact